# Identification of a non-invasive neuroimaging biomarker of prenatal synaptic development

> **NIH NIH R21** · YALE UNIVERSITY · 2020 · $251,250

## Abstract

Project summary and abstract
One of the most profound changes that occurs during gestational development is the rapid increase in the
connections between neurons. Synaptogenesis, or the formation of synapses, that occurs in utero is critical for
subsequent neural development, and several mental and developmental disorders are believed to be the
resultant of alterations in prenatal synaptogenesis. Synaptic quantification, until recently, has required post-
mortem tissue, so direct evidence linking prenatal synaptic disruptions with postnatal neural and behavioral
development has been limited. We have recently developed a novel positron emission tomography (PET)
radioligand ([11C]UCB-J) that targets synaptic vesicle glycoprotein 2A (SV2A), a protein expressed in almost all
synaptic vesicles, and have demonstrated that [11C]UCB-J is able to detect subtle alterations in human
disorders, such as Alzheimer’s disease. We have conducted a pilot study using [11C]UCB-J to quantify synaptic
development throughout prenatal and postnatal development in non-human primates and have found striking
changes in [11C]UCB-J binding that parallel post-mortem measures of synaptogenesis. Therefore,
longitudinally characterization of synaptic density with [11C]UCB-J has the potential to provide unprecedented
insight into the developmental mechanisms that underlie mental illness. This proposal will use [11C]UCB-J to
quantify synapses throughout gestation and the first nine postnatal months in non-human primates to
determine the predictive relationship between prenatal synaptic development and postnatal development of the
brain and cognition. In the first aim, we will quantify SV2A during gestation (post-conception days 120 and 150)
and following birth (postnatal days 15, 30, 60, 120 and 240) to determine if development trajectories of SV2A
co-vary with changes in reward learning, working memory and response inhibition, which are cognitive
domains known to be altered in mental illness. The second aim will determine the relationship between
prenatal SV2A density and magnetic resonance (MR) measures in order to identify a putative MR biomarker of
prenatal synaptic density that could serve as a noninvasive diagnostic tool for use in human infants. Measures
of brain morphometry, myelination and functional connectivity will be longitudinally assessed in the same infant
non-human primates used in Aim 1 following birth (postnatal days 30, 60, 120 and 240) and related to synaptic
and cognitive development trajectories of the same monkey. These studies of normal development in non-
human primates will provide the preliminary data for future studies examining SV2A in animal models of mental
illness, and ultimately lead to the identification of noninvasive MR imaging biomarker of prenatal synaptic
density that can be safely acquired in human infants and children and serve as a diagnostic tool.

## Key facts

- **NIH application ID:** 10148100
- **Project number:** 3R21MH120615-02S1
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Stephanie Mary Groman
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $251,250
- **Award type:** 3
- **Project period:** 2019-08-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148100

## Citation

> US National Institutes of Health, RePORTER application 10148100, Identification of a non-invasive neuroimaging biomarker of prenatal synaptic development (3R21MH120615-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148100. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*